文献速递复苏、休克与脓毒症心脑血管急症

艾司洛尔、向量改变与限量肾上腺素用于院前室颤或无脉性室速

Esmolol, vector change, and dose-capped epinephrine for prehospital ventricular fibrillation or pulseless ventricular tachycardia.
PubMed 文献 · Am J Emerg Med · 2022-11-17
一句话结论院前难治性室颤/无脉性室速中,接受艾司洛尔+向量改变除颤+限量肾上腺素3 mg的EMS组合者持续ROSC率反而显著低于标准ACLS组。

该多中心回顾性队列研究纳入2017年10月18日至2022年3月15日院前心脏骤停且为室颤或无脉性室速、已接受至少3次标准除颤、至少3 mg肾上腺素和300 mg胺碘酮的83例患者,比较实施EMS组合(艾司洛尔、向量改变除颤、限量肾上腺素3 mg)后47例与实施前标准ACLS 36例。组合组持续ROSC(17% vs 58.3%,p<0.001)、任何ROSC(19.1% vs 66.7%,p<0.001)和存活到院(17% vs 55.6%,p<0.001)均显著低于标准ACLS组;出院存活(6.4% vs 16.7%,p=0.17)和出院神经功能完好存活(4.3% vs 5.9%,p=1.00)无显著差异。作者认为该组合未能改善结局。

要点

  • 难治性室颤/无脉性室速(至少3次除颤、至少3 mg肾上腺素、300 mg胺碘酮后)接受EMS组合者持续ROSC仅17%,标准ACLS组58.3%(p<0.001)。
  • EMS组合组任何ROSC 19.1% vs 标准ACLS组66.7%(p<0.001),存活到院17% vs 55.6%(p<0.001),均显著更低。
  • 出院存活组合组6.4% vs 标准ACLS组16.7%(p=0.17),出院神经功能完好存活4.3% vs 5.9%(p=1.00),无显著差异。
  • 该EMS组合包括艾司洛尔给药、向量改变除颤和限量肾上腺素3 mg,用于院前难治性室颤/无脉性室速。

适用人群与场景

  • 院前心脏骤停且初始心律为室颤或无脉性室速、已接受至少3次标准除颤、至少3 mg肾上腺素和300 mg胺碘酮的成人患者(研究纳入标准)。

诊断标准与关键阈值

  • 难治性室颤/无脉性室速定义(研究纳入标准):院前心脏骤停为室颤或无脉性室速,且已接受至少3次标准除颤、至少3 mg肾上腺素和300 mg胺碘酮。
  • 持续ROSC定义:ROSC持续20分钟且无心脏骤停复发。

处置流程与药物剂量

  • EMS组合包括:艾司洛尔给药、向量改变除颤、限量肾上腺素3 mg(原文未写明艾司洛尔剂量、给药途径和频次)。
  • 对照组接受标准ACLS干预。

研究设计与关键结果

  • 多中心回顾性队列研究,纳入2017年10月18日至2022年3月15日院前难治性室颤/无脉性室速患者83例,EMS组合组47例,标准ACLS组36例。
  • 主要终点持续ROSC:EMS组合组17% vs 标准ACLS组58.3%,p<0.001。
  • 任何ROSC:EMS组合组19.1% vs 标准ACLS组66.7%,p<0.001。
  • 存活到院:EMS组合组17% vs 标准ACLS组55.6%,p<0.001。
  • 出院存活:EMS组合组6.4% vs 标准ACLS组16.7%,p=0.17,无显著差异。
  • 出院神经功能完好存活:EMS组合组4.3% vs 标准ACLS组5.9%,p=1.00,无显著差异。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于院前难治性室颤/无脉性室速(至少3次除颤、至少3 mg肾上腺素、300 mg胺碘酮后),接受艾司洛尔、向量改变除颤和限量肾上腺素3 mg的EMS组合者持续ROSC和存活到院率显著低于标准ACLS组,出院神经功能完好存活率低且两组相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Refractory ventricular fibrillation (VF) and pulseless ventricular tachycardia (pVT) cardiac arrest describes a subset of patients who do not respond to standard Advanced Cardiac Life Support (ACLS) interventions and are associated with poor outcomes. Esmolol administration and vector change defibrillation have shown promise in improving outcomes in these patients, however evidence is limited.

OBJECTIVES: This study compares clinical outcomes between patients with prehospital refractory VF/pVT who received an Emergency Medical Service (EMS) bundle, comprised of esmolol administration, vector change defibrillation, and dose-capped epinephrine at 3 mg, to patients who received standard ACLS interventions.

METHODS: This multicenter, retrospective, cohort study evaluated medical records between October 18, 2017 and March 15, 2022. Patients were enrolled if they experienced a prehospital cardiac arrest with the rhythm VF or pVT, had received at least three standard defibrillations, at least 3 mg of epinephrine, and 300 mg of amiodarone. Patients who received the EMS bundle after its implementation were compared to patients who received standard ACLS interventions prior to its implementation. The primary outcome was sustained return of spontaneous circulation (ROSC), defined as ROSC lasting 20 min without recurrence of cardiac arrest. Secondary outcomes included the incidence of any ROSC, survival to hospital arrival, survival at hospital discharge, and neurologically intact survival at hospital discharge.

RESULTS: Eighty-three patients were included in the study. Thirty-six were included in the pre-EMS bundle group and 47 patients were included in the post-EMS bundle group. Patients in the pre-EMS bundle group achieved significantly higher rates of sustained ROSC (58.3% vs 17%, p < 0.001), any ROSC (66.7% vs 19.1%, p < 0.001), and survival to hospital arrival (55.6% vs 17%, p < 0.001). The rates of survival to hospital discharge (16.7% vs 6.4%, p = 0.17) and neurologically intact survival at hospital discharge (5.9% vs 4.3%, p = 1.00) were not significantly different between groups.

CONCLUSIONS: Patients who received the EMS bundle achieved sustained ROSC significantly less often and were less likely to have pulses at hospital arrival. The incidence of neurologically intact survival was low and similar between groups.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Stupca K, Scaturo N, Shomo E, et al. Esmolol, vector change, and dose-capped epinephrine for prehospital ventricular fibrillation or pulseless ventricular tachycardia. Am J Emerg Med. 2022. PMID: 36436299. doi:10.1016/j.ajem.2022.11.019

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。